Cabozantinib Mechanism of Action – Part 3 of an interview with Dr Maha Hussain
Maha Hussain MB ChB is Professor of Medical Oncology at the University of Michigan. I was privileged to interview her about cabozantinib (XL184), a novel drug in development for multiple indications, including prostate cancer.
You can read part 1 of the interview on cabozantinib and pain here, and part 2 about the bone effect seen with cabozantinib, here.
In this final post, Dr Hussain discusses the scientific rationale behind the mechanism of action for cabozantinib, a multi-kinase inhibitor of C-MET, VEGF and others. She also shares her thoughts on where the scientific data suggests it should have most impact on prostate cancer. I have emphasized in bold a few sections that stood out to me.
